• In August 2026, ACADIA Pharmaceuticals Inc. reported past second-quarter 2026 results showing revenue of US$307.96 million and net income of US$31.5 million, with earnings per share from continuing operations of US$0.18, alongside higher year-to-date revenue but lower net income compared with the same period in 2025.
• On the same day, the company raised its full-year 2026 guidance, lifting projected total revenues to US$1.24–US$1.30 billion and increasing expected DAYBUE global net product sales, signalling greater confidence in its key CNS and rare disease franchises.
• We’ll now examine how ACADIA’s raised full-year 2026 revenue guidance reshapes its existing investment narrative and risk-reward profile for investors.

The future of work is here. Discover the 37 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

ACADIA Pharmaceuticals Investment Narrative Recap

To own ACADIA, you need to believe its focus on CNS and rare diseases can support durable revenue from NUPLAZID and DAYBUE while funding a broader pipeline. The raised 2026 revenue guidance tightens the near term focus on execution in these two franchises, but it does not materially change the biggest current risk, which is ACADIA’s dependence on a small number of high-value products in markets exposed to pricing and reimbursement pressure.

The most relevant recent announcement here is the updated 2026 guidance lifting total revenue expectations to US$1.24–US$1.30 billion and increasing projected DAYBUE global net product sales to US$480–US$510 million. This guidance ties directly into the key catalyst of expanding DAYBUE’s commercial footprint and validates how central trofinetide uptake has become to ACADIA’s near term growth story and to investors’ focus on its risk reward trade off.

Yet despite stronger 2026 guidance, investors should be aware that ACADIA’s reliance on NUPLAZID and DAYBUE still leaves the story vulnerable if...

ACADIA Pharmaceuticals' narrative projects $1.7 billion revenue and $317.1 million earnings by 2029. This implies 13.5% yearly revenue growth but an earnings decrease of about $63 million from $380.5 million today.

Uncover how ACADIA Pharmaceuticals' forecasts yield a $33.25 fair value, a 15% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already assuming revenue could reach about US$1.9 billion by 2029 and earnings about US$514 million, so when you compare that to today’s higher 2026 guidance and the heavy dependence on two core drugs, you can see how views on ACADIA’s potential, and its risks, can differ widely and may shift again as this new information is absorbed.

Explore 6 other fair value estimates on ACADIA Pharmaceuticals - why the stock might be worth over 3x more than the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your ACADIA Pharmaceuticals research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free ACADIA Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate ACADIA Pharmaceuticals' overall financial health at a glance.

Contemplating Other Strategies?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 28 best rare earth metal stocks of the very few that mine this essential strategic resource.
• Capitalize on the AI infrastructure supercycle with our selection of the 56 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.